期刊文献+

细胞毒性药物不合理医嘱调查分析

Cytotoxic Drugs Investigation of Irrational Prescriptions
下载PDF
导出
摘要 目的:分析细胞毒性药物不合理医嘱的主要类型原因及应对策略。方法对我院2013年2月~2015年5月用药配置中心5000例患者的细胞毒性药物长期医嘱进行审核,并按照类型的不同对其进行划分。结果5000例细胞毒性药物长期医嘱中,不合理医嘱例数为34例,比例为0.68%。34例患者的不合理医嘱主要可分为药物用量及用法不当、溶媒选择不合理、溶媒量偏多、溶媒量偏少、其他等类型,百分比分别为11.76%、44.12%、20.59%、14.71%、8.82%。结论加强对细胞毒性药物不合理医嘱的类型、原因分析,同时提升药师对细胞毒性药物应用重视程度,并加强细胞毒性药物长期医嘱的审核处理,可有效减少不合理医嘱的发生,从而有效确保细胞毒性药物临床应用的安全性和有效性。 Objective To analyze the cytotoxic drugs and irrational prescriptions of the main types of coping strategies.MethodsFrom February 2013 to May 2015, cytotoxic drug in drug distribution center configuration of 5 000 cases of patients with long-term prescription were analyzed, and in accordance with the different types of its division. Results5 000 of cytotoxic drugs in long-term medical advice, medical advice unreasonable number of cases 34 cases, the ratio was 0.68%. 34 patients of irrational prescriptions can be divided into the amount of drugs and improper usage, vehicle selection unreasonable, solvent volume side, solvent less than normal, the other other types, percentages were 11.76%, 44.12%, 20.59%, 14.71%, 8.82%.Conclusion Strengthening of cytotoxic drugs irrational prescriptions of type, cause analysis, while increasing emphasis on pharmacists application of cytotoxic drugs, while strengthening the review process of long-term prescription of cytotoxic drugs, can effectively reduce the incidence of irrational prescriptions, thereby, to ensure the safety and efifcacy of cytotoxic drugs in clinical applications.
作者 张凤红
出处 《中国继续医学教育》 2015年第30期168-169,共2页 China Continuing Medical Education
关键词 细胞毒性药物 不合理医嘱 安全性 Cytotoxic drugs Irrational prescriptions Security
  • 相关文献

参考文献3

二级参考文献19

  • 1李运景,唐蕾,郭锡华.静脉输注药物集中配置与临床药学的开展[J].中药材,2005,28(1):62-64. 被引量:20
  • 2韩钢,方红梅,章辉.我院静脉药物配置中心开展的临床药学工作[J].中华医院管理杂志,2006,22(12):815-816. 被引量:17
  • 3Launchbury AP, Habboubi N. Epruibicin and doxorubicin.. A comparison of their characteristics, therapeutic activity and toxic ity [J]. Cancer Treat Rev, 1993, 19 (3): 197-228.
  • 4Oermanakis I, Anagnostatou N, Kalmanti M. Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxici ty [J]. Pediatr Blood Cancer, 2008, 51 (3) : 327-333.
  • 5Pouillart P. Evaluating the role of dexrazoxane as a cardio protectant in cancer patients receiving anthracyclines [J]. Cancer Treat Rev, 2004, 30 (7): 643-650.
  • 6FDA Drug Safety Communication. Abnormal heart rhythms as- sociated with llse of Anzemet (dolasetron mesylate) [EB/OL] . (2011 04 02) [-2011-04-16 ]http: //www. fda. gov/Drugs/ DrugSafety/uern237081. htm.
  • 7Longfield V. Compatibility and stability of 5 HT3 receptor antagonists.- a pharmacology review [J]. Oncol Nurs Fo- rum, 2002, 29 (20): 1469-1482.
  • 8Paz-Ares LG, Smith MR. Genitourinary malignancies [J]. Cancer Chemother Biol Response Modi, 2001, (19) : 573- 595.
  • 9张蕾,赵荣生,翟所迪.神经科专科药师的特点与培养路径探讨[J].中国药房,2008,19(8):630-632. 被引量:2
  • 10钟海利,郑志燕.药师查房中应关注的抗肿瘤药物不良反应及防治对策[J].中国现代医生,2008,46(36):43-44. 被引量:11

共引文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部